Key clinical point: A decision support tool allows clinicians to predict the likelihood that a patient with active Crohn’s disease will experience clinical remission on ustekinumab.

Major finding: Crohn’s disease patients with a score of 5 or more on the clinical decision-support tool had a 57% clinical remission rate after 16 weeks on ustekinumab, compared with rates of 34% and 21% in those with intermediate and low scores, respectively.

Study details: The clinical prediction model and decision support tool was created through analysis of data on 781 ustekinumab-treated patients in phase 3 randomized trials.

Disclosures: The decision support tool was developed through a research grant from Janssen, which markets ustekinumab.